When Donald Trump returned to the White House in January 2025, the question wasn't whether his administration would change the direction of US health policy – it was how quickly, how deeply
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.